Meniere’s Research Fund Inc.

 Meniere’s Disease has devastating effects on the lives of those afflicted and on those who care for them. Working lives are disrupted and careers brought to an end. The normally ordered and busy lives of otherwise healthy people, suddenly become totally unreliable.

The unresolved questions surrounding the condition have been tackled for nearly 150 years without finally identifying the cause and a possible cure. While medical and surgical advances to alleviate the affliction have been encouraging, the Meniere’s Research Fund Inc (the Fund), a not for profit fund raising group run by volunteers established in 2002 as a development from the Meniere’s Support Group of NSW (now disbanded), has been stepping up the research effort. The support work across Australia is now the responsibility of Meniere’s Australia Inc.

The research program developed by the Professorial Research Committee of the Fund has  explored new areas of the inner ear. Dr Yasuhiro Chihara, who joined us in April 2011, has been working with Dr Daniel Brown, our initial Research Fellow, on trials using Vasopressin to asses its effect on creating hydrops (swelling of endolymph fluid thought to underlie the cause of MD attacks). Another exciting area to be explored, perceived by both Mr Stephen Spring and Professor Gibson, is now on the cusp of new trials to validate or disprove the suppressive effect of a known drug not previously successfully administered elsewhere.

Our aim is to build up a strong research team in Sydney, to explore and build on the findings from Meniere’s research being carried out by scientists in Australia and other countries. We have been able to recruit our team due to the support we have received from our generous donors.

We are confident that with your help in maintaining and expanding the world’s first laboratory dedicated entirely to studying Meniere’s Disease, established here at the Brain and Mind Research Institute, our program will lead to enhanced early detection, preventative strategies and superior treatments sufficiently alleviating the condition to make sufferers able to again lead a relatively normal life.



If you are an Australian taxpayer, a tax deductable donation to us means you give to the Fund and claim a refund from the Australian Tax Office.  International donors seeking a tax deduction should check with their local advisors that Sydney University Medical Foundation’s charitable status is recognised by that country.


For USA donations, the University of Sydney USA Foundation provides a tax advantaged way for USA taxpayers to support Meniere’s research at the University of Sydney by donating to our Fund.  The foundation is incorporated in Washington, DC as a tax-exempt 501(c)(3) charitable organisation. Gifts to the Foundation can be claimed as tax deductions by US taxpayers.  US donators, please with an instruction to direct your donation to The Menieres Research Fund, your preferred method of payment and information required to have the claimable receipt forwarded to you.  Alternately, write or telephone, The University of Sydney USA Foundation, PO Box 3906, Ithaca, NY 14852-3906. Phone: + 1 410 733 9444


The Friends of the University of Sydney UK Trust allows alumni and friends residing in the UK to support the University of Sydney through tax-advantaged giving. Gifts to the trust are tax deductible for UK residents on both income and estate taxes. Donations can be made to the Trust online ( or by contacting the Trust at Friends of the University of Sydney UK Trust, Administration Manager,The Britain-Australia Society, 59 Buckingham Gate, London UK SW1E 6AJ Phone: +44 (0)20 7630 1075 Fax: +44 (0)20 7828 2260 Email:

Whether donating on-line or by other means, please specify that you wish your donations to be used for Meniere’s research at the University of Sydney – Sydney Medical School Foundation

Whirled Foundation

Unfortunately, in March 2018 the Whirled Foundation (previously Meniere’s Australia) reached a point where it was no longer financially viable to continue to operate. They are in the process of becoming insolvent.

It is anticipated that as part of this process, their remaining assets will be handed over to the Meniere’s Research Fund Inc.

However, at the Special General Meeting of the Whirled Foundation in March 2018, the MRFI were advised that Beatrice Te would be considering purchasing the rights to the Whirled website and facebook pages, with the intent to continue on and online support resource for Meniere’s sufferers throughout Australia.

We will keep you updated on the progress of this change-over, and would like to remind Meniere’s sufferers to keep an eye on the Whirled Foundation’s website & Facebook pages.


Novel Pharmacological Treatments

Recently, the Meniere’s research laboratory has been exploring the development of a novel treatment for endolymphatic hydrops. The premise is that if a chemical could be applied to the inner ear which temporarily increased the permeability of the endolymphatic compartment, it may provide hydrostatic relief of hydrops (kind of like deflating a balloon for a while). Currently, there are a host of chemicals that are used in pharmacology, and are FDA and TGA approved, which provide such a temporary (i.e. hours) increase in the permeability of membranes.

We began trialing ‘sodium caprate’, which is often used to temporarily permeabilize the lining of the intestines, but has recently been used to increase the fluid permeability of inner ear tissues. At moderate concentrations, sodium caprate certainly increases the permeability of membranes like the vasculature overlying the cochlea:

Right) The outer vasculature of the cochlea imaged using our Light Sheet Microscope, with fluorescent contrast agents perfused through blood. Left) In an ear where 20mM sodium caprate has been applied to the middle ear, demonstrating the blood vessels are permeabilized and leak blood onto the cochlear wall. Images are presented in low-resolution.

Moreover, sodium caprate can be applied at lower concentrations, directly to the endolymphatic compartment, increasing its permeability, and allowing perilymph and endolymph to mix temporarily. However, we have yet to perfect methods of applying sodium caprate via and intra-tympanic approach (which would be used clinically), enabling endolymph compartment to be temporarily permeabilized. We currently believe this is due to the complex pharmacokinetics of the inner ear, which make drug delivery to the inner ear a tricky business.



August 2016 Update

Our recent publication: “Endolymph movement visualized with light sheet fluorescence microscopy in an acute hydrops model“, used our Light Sheet Fluorescence Microscope to suggest that at some stage during endolymphatic hydrops, some mechanism ‘triggers’ the rapid uptake of endolymph into the endolymphatic sac, and most likely the utricle and semicircular canals. This mechanism may explain the sudden vertigo attacks observed in Meniere’s.

Moreover, the result highlight that there is an apparent uptake of endolymph into the micro-vasculature surrounding the endolymphatic duct. This uptake appears (at first glance) to be a ‘paracellular’ uptake (i.e. the endolymph fluid flows directly into the microvasculature, rather than flowing through cells). 7
Figure from Brown et al., 2016 showing uptake of fluorescent fluid marker into the microcanals surrounding the endolymphatic duct.

This is a remarkable possibility, because it suggests that the endolymphatic compartment isn’t actually a ‘closed’ compartment as it is typically viewed, but rather this pathway normally allows endolymph to ‘leak’ out into either trabeculated bone or blood. Interestingly, there was a series of histological studies performed by Prof. Fred Linthicium between 2010-2014, where they noted the abnormal morphology of the microcanals surrounding the endolymphatic compartment in Meniere’s sufferers as compared to non-Meniere’s ears. Currently, the link between these microcanals and Meniere’s disease is unclear, although their apparent involvement in endolymph volume regulation makes them prime candidates for further study and pharmacological targeting.

Linthicum et al

Figure from Linthicium et al., 2014, showing a 3D reconstruction of the microcanals in human temporal bones. In previous studies by this research group, they have noted that the canals appear to be decellularized in Meniere’s sufferers.

March 2016 Update

March 2016 Update:

Following the 2016 Prosper Meniere’s Society Meeting in Austria, it is probably a good time to provide an update of the current research being performed at The University of Sydney, Meniere’s Laboratory.

There are numerous lines of research that we have either undertaken over last few years, or are currently undertaking. Here‘s a brief summary of each project for the layman. As you can see, the below list of recent projects is extensive, and given that the research team consists mostly of Dr Brown, a couple of students, and a couple of clinical collaborators, it is perhaps easy to appreciate the slow-progress of the research overall. That is, we appreciate that Meniere’s sufferers are desperate for a glorious breakthrough, but this is unlikely to happen overnight, and the Laboratory does not currently have the resources most people in the public may perceive that it does. At one level, we punch-above-our weight, but we are still hamstrung by the moderate nature of the laboratory’s team. This is, however, rapidly changing, as the laboratory establishes more of a profile at the University and Internationally. What is needed, and what the MRFI are now looking towards, is to grow the lab team, by recruiting additional, experienced laboratory researchers to compliment Dr Brown’s program.

Aquaporin over-expression as a model for Hydrops.

Over the last 15 years, several researchers have focused on the idea that many forms of Meniere’s disease may be due to an abnormal expression of water transport channels called aquaporins. Specifically, a number of studies have reported that experimental animals who have been treated with hormones that up-regulate the expression of aquaporins develop endolymphatic hydrops, and related hearing and balance symptoms. Between 2012-2013 we explored this animal model by chronically implanting mini-osmotic pumps into guinea pigs to deliver vasopressin (a hormone that upregulates aquaporin expression) over a 2-3 week period (Chihara et al., 2013). Ultimately, we found the effects to be minimal, and most likely insufficient to explain the symptoms observed in Meniere’s disease patients. We subsequently moved on from this model, but in the subsequent years others have continued to explore the involvement of aquaporins in Meniere’s, demonstrating new findings that may entice us to revisit the model in the future. For now, we think that it is unlikely that an abnormal level of hormones that regulate aquaporin expression is the cause of Meniere’s disease in a relevant number of sufferers.

Cause of Vertigo attacks

One main-stay of our research over the last few years has been the investigation of the link between endolymphatic hydrops, and the symptoms of Meniere’s disease. Arguably, from 2005 until the last couple of years, many researchers felt that endolymphatic hydrops was not the cause of Meniere’s symptoms, but rather just an epiphenomenon. This view resulted from a seminal study by Merchant et al., (2005), who examined temporal boned from deceased people, and reported that whilst all Meniere’s sufferers had hydrops, many people who were not diagnoses with Meniere’s disease also had hydrops. This report was heavily cited, and ‘became clouded’ in the research world to be taken as though hydrops doesn’t cause hearing or balance symptoms, and that normally hearing/balance people can have hydrops.

However, a close inspection of the Merchant study reveals that the non-Meniere’s ears with hydrops all had some form of hearing or balance disorder, it’s just that they didn’t fit the criteria for a Meniere’s diagnosis. More recently, MRI studies have demonstrated a clear association between endolymphatic hydrops and Meniere’s disease (or related inner ear problems).

Additionally, we have performed numerous studies where we have artificially created endolymphatic hydrops in the inner ears of experimental animals, demonstrating that hydrops can indeed underlie the symptoms of Meniere’s, including the sudden episodes of vestibular dysfunction. Traditionally, it was thought that hydrops (a swelling of the membranous labyrinth) eventually caused a rupture of the membranous labyrinth, resulting in a mixing of the inner ear fluids (perilymph and endolymph), and a transient potassium toxicity of the vestibular hair cells. This is known as the “Rupture Theory”. We have performed an extensive, if not exhaustive series of experiments to determine if a rupture of the membranous labyrinth causes sudden vestibular problems… ultimately, we have failed to find sufficient evidence that ruptures underlie the episodes of vestibular dysfunction. Rather, our research points towards a sudden re-distribution of the endolymph fluid within the membranous labyrinth, possibly involving the action of various morphological ‘valves’ that separate portions of the inner ear (Brown et al., 2013a,b; Brown et al., 2016). It seems as though endolymph volume builds up in one part of the ear (the cochlea), increasing fluid pressure and disturbing cochlear hair cells, until the pressure forces open one of these valves, releasing pressure in one compartment, but increasing it in another (also causing a sudden ionic disturbance).

The importance of understanding the role hydrops plays in hearing and balance symptoms is two-fold. First, we can now focus on researching disorders that may cause abnormal fluid volume regulation per se, rather than researching disorders that cause fluctuating hearing and balance symptoms – but may or may not lead to hydrops (e.g. a viral infection of the VIIIth nerve).

DPOAE bias

It seems everyone wants to see more randomized, placebo controlled trials of treatments for Meniere’s. First, it’s important to understand that such trials are difficult to get going, and almost always require the involvement of multiple hospitals/specialized clinics, with nurses, clinicians, and biostatisticians who are experienced in running such trials. Secondly, because Meniere’s symptoms naturally fluctuate, the trial must be maintained over a long period of time (>6 months at least) to ensure efficacy, you need close to a hundred or more participants, and you must make sure that all those participants have Meniere’s disease of the ‘right’ kind. Trials are particularly difficult here because we lack a tool for the simple diagnosis of the disease itself. That is, we cannot simply rely on patients providing feedback about how they are feeling, because the placebo effect in Meniere’s disease is very large.

If we had a tool whereby we could easily measure Meniere’s disease, or if you like, hydrops (assuming hydrops directly correlates with the course of the disease), then trials would be an order of magnitude easier to perform, because we wouldn’t need a placebo group, and we wouldn’t need to wait for the full progression of symptoms.

In 2012 we developed a non-invasive method of objectively estimating the level of hydrops in Meniere’s sufferers. This test involves using low-frequency modulated ‘Distortion Product Otoacoustic Emissions’ (DPOAE-bias). The test works really well in people who still have good hearing, and involves just an ear-canalphone like setup. We are currently looking for industry partners who can help develop the test into standard audiometric equipment, so that we can test many more people, and incorporate the test into clinical trials.


Still working on the following updates… more to come….

Light Sheet Fluorescent Microscope

UVL plus CI

CI impedance Fluctuation

Scala Media Pressure Regulation

Vestibular Efferent System

Sodium Caprate

LPS induced Hydrops

Comparison of membranous labyrinth in MD patients vs. pre-clinical models

Dr Mukherjee Funding Success

In addition to Dr Brown’s recent fellowship, Dr Payal Mukherjee has also been awarded a 3 year Project grant from the Garnett Passe and Rodney Williams Memorial Foundation.

Payal aims to develop new techniques for 3D printing biological tissues for use in the inner ear, using scaffolding and in vitro techniques. The project will be developed in collaboration with Prof. Hala Zreiqat from the Biomaterials & Tissue Engineering Research Unit at Sydney University.

Congratulations Payal.


Funding Success 2016

Wow – What a way to start the year.

Dr Daniel Brown has been awarded a 5 year “Senior/Principal Research Fellowship” by the Garnett Passe and Rodney Williams Memorial Foundation.

This is a significant award, and a great honor.

The award stems from Daniel’s development of the Light Sheet Microscope, along with the novel methods for investigating endolymph fluid dynamics. Here, Daniel plans to develop a new experimental model of immune-mediated endolymphatic hydrops, to use his Light Sheet Microscope to demonstrate the dynamics of hydrops development, and then to develop novel therapies for hydrops.

Stay posted for more progress with this research.

Funding Success

2015 – 2018: Dr Payal Mukherjee, Dr Adrienne Morey, Em. Prof Bill Gibson and Dr Daniel Brown were awarded a 3 year Conjoint Project Grant by the Garnett Pass & Rodney Williams Memorial Foundation. The project will examine changes in the tissues extracted from Meniere’s sufferers undergoing ablative surgery (i.e. labyrinthectomy) compared to non Meniere’s sufferers and animal models of Meniere’s.

The project draws on the surgical expertise of Dr Mukherjee and Em. Prof. Gibson, the histopathology of Dr Adrienne Morey, and the experimental research of Dr Brown. A number of Sydney Based Clinicians are also involved in the project, providing clinical data and samples.

This project aims to determine the possibility that abnormal tissue thickening in the inner ear is the cause of endolymphatic hydrops and the symptoms of the disease. The team currently has a small ‘bank’ off tissues from a number of patients, and is developing the animal model to match the observed histological changes.